Cardiovascular effects of incretin-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis
Shanshan Wu,Jun Yang,Ting Cai,Yang Xu,Zhirong Yang,Yuan Zhang,Sanbao Chai,Feng Sun,Siyan Zhan
DOI: https://doi.org/10.1016/S2213-8587(16)30373-4
IF: 44.867
2016-01-01
The Lancet Diabetes & Endocrinology
Abstract:Abstract Background Concerns about the cardiovascular safety of incretin-based therapies, which include dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists, in patients with type 2 diabetes have been raised. We aimed to systematically assess the cardiovascular effects of incretin-based therapies in patients with type 2 diabetes. Methods In this systematic review and network meta-analysis, we searched MEDLINE, Embase, the Cochrane library, and ClinicalTrials.gov from inception to April 28, 2016, for reports of randomised controlled trials. We included reports with available data comparing incretin-based therapies with placebo and traditional antidiabetic drugs in patients with type 2 diabetes, with a minimum follow-up period of 12 weeks, and we extracted data from these reports. The main outcome was a composite of major adverse cardiovascular events (including cardiovascular death, myocardial infarction, and stroke, as defined by the US Food and Drug Administration) and heart failure. We used a random-effects model to calculate odds ratios (ORs) with 95% CI, and did a network meta-analysis to supplement direct comparisons. This study is registered with PROSPERO, number CRD42015020395. Findings Of 4873 trials identified in the search, 271 trials with eight treatments (incretin-based therapies, placebo, and six traditional antidiabetic drugs—metformin, insulin, sulfonylureas, thiazolidinediones, alpha-glucosidase inhibitors, and sodium-glucose co-transporter 2 inhibitors) and 162 729 patients were included in analysis. In pairwise meta-analysis, incretin-based therapies had a significantly decreased risk of cardiovascular events compared with placebo (OR 0·75, 95% CI 0·64–0·87) and sulfonylureas (0·78, 0·61–0·98). However, in network meta-analysis, the protective effect of incretin-based therapies on cardiovascular events was not detected compared with placebo (0·94, 0·87–1·02) and was evident only compared with sulfonylureas (0·77, 0·61–0·98). Incretin-based therapies did not have an increased cardiovascular risk compared with other traditional antidiabetic drugs in both pairwise and network meta-analyses. Ranking probability analysis showed that incretin-based therapies had the lowest cardiovascular risk among all eight treatments with a probability of 67·5%, followed by alpha-glucosidase inhibitors (65·2%) and sodium-glucose co-transporter 2 inhibitors (61·3%). Interpretation Incretin-based therapies seems to be associated with a decreased cardiovascular risk compared with placebo and sulfonylurea, and did not show any increased risk of cardiovascular events compared with other traditional antidiabetic drugs. Funding National Natural Science Foundation of China (81302508).